| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 5.2 Billion |
| Market Size in 2026 | USD 5.4 Billion |
| Market Size by 2032 | USD 7.2 Billion |
| Projected CAGR | 4.7% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Semi-Consolidated |
Explore the market potential with our data-driven report
The liquid handling system market size was USD 5.2 billion for 2025, and it will grow by 4.7% during 2026–2032, to reach USD 7.2 billion by 2032.
The growth is attributed to the booming life sciences industry, increasing prevalence of chronic diseases, and rising investment by companies for developing innovative and effective therapeutic agents. The U.S. National Institutes of Health allocated more than USD 47 billion in medical research funding in 2024, supporting biomedical and clinical research activities and contributing to the demand for automated laboratory instruments including liquid handling systems.
Additionally, the increasing wave of pharmaceutical patent expirations is compelling companies to accelerate drug discovery and early-stage research activities, thereby driving demand for high-throughput and precise liquid handling systems. Furthermore, emerging economies such as China and India are offering significant growth opportunities due to expanding healthcare infrastructure, increasing R&D investments, and the growing adoption of laboratory automation technologies across research institutions and pharmaceutical companies.
The liquid handling system market is witnessing a major trend toward increasing automation of laboratory workflows. High-throughput screening systems and robotics-enabled laboratory platforms are driving this shift. Automated liquid handling systems are increasingly replacing manual processes in drug discovery, genomics, and proteomics. Reduced human error, improved reproducibility, and accelerated experimental timelines make automated platforms operationally superior to manual execution at scale. According to the U.S. Food and Drug Administration, the number of novel drug approvals has increased in recent years, with over 50 new drug approvals reported in several recent cycles, necessitating high-throughput screening and automated sample processing systems.
Government-supported biomedical innovation programs are reinforcing this trend. The U.S. National Institutes of Health continues to fund large-scale genomics and precision medicine initiatives. These programs support the adoption of advanced laboratory technologies, including automated liquid handling platforms, across funded research institutions. The European Commission's Horizon Europe program has allocated over EUR 95 billion for research and innovation, with a significant portion directed toward life sciences and biotechnology infrastructure. This allocation is accelerating the deployment of automated liquid handling systems in research institutions across member states.
Sustained expansion of global pharmaceutical and genomic research activity is a primary external force propelling demand for advanced liquid handling systems. Automated platforms capable of screening large compound libraries with sub-microliter accuracy have become essential for laboratory workflows as drug developers pursue compressed development timelines for oncology, rare disease, and biologics programs. Additionally, the growing focus on complex biologics, cell and gene therapies, and mRNA-based treatments is increasing the need for precise and scalable liquid handling systems to support advanced and sensitive experimental workflows.
The broader pharmaceutical R&D pipeline also reinforces this demand trajectory. Patent expirations affecting more than USD 300 billion in pharmaceutical revenues between 2025 and 2030 are compelling pharmaceutical companies to intensify early-stage discovery activity. Higher volumes of compound screening follow, and automated liquid handling infrastructure is the enabling layer that allows those programs to execute efficiently and reproducibly.
Despite strong macro-level demand, capital intensity and technical skill requirements represent binding constraints on market expansion. Small and mid-sized laboratories, academic institutions with limited procurement budgets, and emerging market facilities face the steepest access barriers. Fully automated liquid handling workstations typically require initial investments ranging from USD 100,000 to over USD 1 million depending on system complexity. Software integration, calibration services, and proprietary consumables add further expenditure beyond the capital outlay. These upfront costs create substantial barriers for smaller organizations that cannot readily demonstrate return on investment within standard procurement cycles.
Additionally, compounding the capital constraint is a persistent shortage of skilled laboratory personnel qualified to operate, validate, and maintain sophisticated automated platforms, which directly limits equipment utilization and slows automation adoption across both developed and developing regions. This skills deficit directly limits the effective utilization of installed equipment and slows automation adoption. Limited vendor service networks and constrained training ecosystems reduce confidence in automation investments among facilities that have already cleared the capital threshold. The industry is responding through modular platform designs and subscription-based access models, and vendor-led training programs are broadening the qualified operator base. These initiatives will take time to address adoption barriers, moderating the pace of market penetration across cost-sensitive segments over the near to medium term.
A structural opportunity is emerging from the rapid development of biopharma ecosystems in Asia Pacific, Latin America, and the Middle East. Laboratory markets in these regions, which earlier had limited adoption of advanced automation technologies, are now increasingly adopting automated liquid handling systems as research activities expand and laboratory infrastructure improves. India's bioeconomy, as reported by the Department of Biotechnology (DBT), Government of India, surged from USD 10 billion in 2014 to over USD 130 billion in 2024, with projections toward USD 300 billion. The country's expanding pharmaceutical manufacturing base and CRO sector are generating direct demand for scalable liquid handling solutions.
Shared-use automation hubs are lowering the capital barrier to adoption, enabling startups and smaller research organizations to access high-precision instrumentation without full ownership costs. In the Middle East, Saudi Arabia’s National Biotechnology Strategy aims to create 11,000 biotech jobs by 2030 and contribute USD 34.6 billion to non-oil GDP by 2040, supporting the adoption of advanced liquid handling systems. As regulatory frameworks in these markets mature and life sciences R&D spending grows, liquid handling vendors capable of establishing local manufacturing presence are well-positioned to capture disproportionate share. Distribution depth and in-country service infrastructure will determine which vendors convert that positioning into sustained revenue.
The automated category holds the largest market share, of 60%, in 2025, and it will have the highest CAGR, of approximately 5.2%, driven by increasing demand for high-throughput laboratory workflows in pharmaceutical and biotechnology industries. These systems significantly improve accuracy, reduce human error, and increase processing speed, making them essential in modern drug discovery and genomics research environments. Government-funded biomedical research programs, particularly in the United States and Europe, are accelerating adoption of automated systems in research laboratories.
The increasing complexity of drug development pipelines is further reinforcing automation demand. Additionally, pharmaceutical companies are increasingly integrating robotics and AI-driven laboratory systems to streamline research workflows and reduce time-to-market for new therapies. For instance, Tecan Group has introduced advanced automated liquid handling platforms such as the Fluent Automation Workstation, designed to enhance throughput and precision in life sciences research, supporting the growing demand for fully automated laboratory workflows.
The types analyzed in this report are:
The pipettes category holds the largest market share, of 35%, in 2025, driven by widespread use in basic laboratory workflows across research institutes, pharmaceutical companies, and diagnostic laboratories. Pipettes remain fundamental instruments in liquid handling applications due to their versatility, precision, and low operational cost. Additionally, manual and electronic pipettes continue to be widely used, particularly in small- and mid-scale laboratories where full automation adoption remains limited. For instance, Eppendorf SE has introduced advanced electronic pipetting systems such as the Xplorer and Xplorer plus pipettes, designed to improve accuracy, ergonomics, and workflow efficiency in routine laboratory applications.
The consumables category will have the highest CAGR, driven by increasing usage of disposable tips, cartridges, and reagents in automated workflows. Rising adoption of contamination-free laboratory practices and high-throughput screening systems is significantly increasing demand for consumables. The U.S. National Institutes of Health Molecular Libraries Program supports high-throughput screening using a shared repository of more than 300,000 chemically diverse compounds, highlighting the substantial scale of consumable usage required for systematic drug discovery workflows. Government healthcare and laboratory safety regulations further reinforce the shift toward disposable laboratory components in clinical and research settings.
The products analyzed in this report are:
The drug discovery category holds the largest market share, of 45%, in 2025, driven by extensive pharmaceutical R&D activities and increasing investment in new drug development. Liquid handling systems are critical in high-throughput screening, compound testing, and assay development, making them indispensable in pharmaceutical research pipelines.
The genomics category will have the highest CAGR, of approximately 4.9%, driven by rapid advancements in DNA sequencing technologies and increasing adoption of precision medicine approaches. The increasing scale of genomic testing and sequencing projects is further driving demand for high-throughput and accurate sample processing systems. Government-funded genome research initiatives, including NIH programs in the United States, are significantly accelerating adoption of automated liquid handling systems in genomics laboratories worldwide.
The applications analyzed in this report are:
The biotechnology & pharmaceutical companies category holds the largest market share, of 45%, in 2025, and it will have the highest CAGR, driven by large-scale deployment of liquid handling systems across R&D, quality control, and clinical workflows, supported by stringent GLP/GMP compliance requirements and the need for high-throughput drug discovery. Increasing investment in complex therapeutic areas such as biologics, cell and gene therapies, and mRNA-based treatments is further driving demand for advanced liquid handling systems. Additionally, according to the European Federation of Pharmaceutical Industries and Associations, the pharmaceutical industry invested approximately EUR 55 billion in R&D across Europe in 2024, supporting continued adoption of automated laboratory technologies.
The end users analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share, of 40%, in 2025, due to the increasing number of mergers & acquisitions among biotechnology companies. The growing pharmaceutical and biotechnology industries are having a positive impact on the market growth. For instance, Thermo Fisher Scientific continues to invest heavily in expanding its bioproduction and laboratory solutions capabilities, including automated liquid handling technologies, to support increasing demand from pharmaceutical and biotechnology customers in the region.
Canada is also contributing significantly to regional market growth, supported by increasing government funding for life sciences research and a growing biotechnology sector. Initiatives by agencies such as the Canadian Institutes of Health Research are promoting advanced biomedical research and innovation, which is driving the adoption of laboratory automation technologies, including liquid handling systems, across academic and research institutions.
The U.S. is largest country within North America liquid handling system market, due to the presence of a large number of major healthcare device and pharmaceutical companies and the increase in the need for high-throughput sample processing and laboratory automation in research workflows. Additionally, the U.S. continues to lead in pharmaceutical R&D investment, with member companies of the Pharmaceutical Research and Manufacturers of America having invested over USD 1 trillion in research and development since 2000, supporting strong demand for advanced laboratory automation technologies, including liquid handling systems.
Asia-Pacific will have the highest CAGR, of approximately 5.6%, during the forecast period, attributed to the rise in the investments in the field of biotechnology. In APAC, the China market held the largest revenue share in 2025, due to a large number of R&D activities underway in the life sciences industry in the country. Additionally, China’s biotechnology sector is supported by strong government initiatives such as the Made in China 2025 strategy, which prioritizes biopharmaceutical innovation and advanced laboratory infrastructure, thereby supporting the adoption of automated liquid handling systems.
Japan has contributed significantly to the Asia-Pacific market as well. The country is witnessing collaborations among various industry participants and stakeholders, such as the International Nucleotide Sequence Database Collaboration (INSDC) between the European Bioinformatics Institute (EMBL-EBI), the National Centre of Biotechnology Information (NCBI) in the U.S., and the DNA Data Bank of Japan (DDBJ).
India is the fastest-growing country market within Asia Pacific, fueled by a combination of government-driven genomic initiatives, a rapidly expanding biotech sector, and rising CRO activity. The Department of Biotechnology (DBT), Government of India completed the Genome India Project in January 2025, generating whole-genome sequencing data from more than 10,000 individuals across a consortium of 20 institutions, supporting demand for automated liquid handling platforms used in high-throughput genomics workflows. The project involved 20 institutions and established one of the country's largest genomics datasets. The expansion of pharmaceutical manufacturing hubs in Hyderabad, Pune, and Ahmedabad, combined with the growing CRO sector serving global clinical trial outsourcing, is positioning India as one of the most dynamic demand markets for precision liquid handling solutions in the region.
The regions and countries analysed in this report are:
The market is semi-consolidated, characterized by the dominance of a limited number of well-established life sciences companies with extensive product portfolios and strong global presence. This structure is driven by high capital requirements for developing automated platforms, coupled with the complexity of integrating these systems into GLP/GMP-compliant laboratory environments. Long validation cycles and stringent regulatory requirements further favor incumbent players with proven systems. Additionally, proprietary consumables and software ecosystems create significant switching costs for end users. Although emerging and niche players are entering the market with cost-effective solutions, established vendors continue to dominate high-value and regulated segments, maintaining a semi-consolidated competitive landscape.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages